Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which endometrioma treatment best protects fertility?

NCT ID NCT05637073

Disease control Sponsor: University of Valencia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study compares three common approaches for managing endometriomas (ovarian cysts caused by endometriosis): surgical removal, daily hormone therapy with dienogest, or regular ultrasound monitoring. Researchers will measure how each option affects ovarian reserve—a key marker of fertility—by tracking levels of anti-Mullerian hormone over one year. The study includes premenopausal women aged 18–39 with small to moderate-sized cysts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dienogest
What this could lead to
If successful, this study could help women with endometrioma choose a treatment that better preserves their fertility potential.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by patient choice. The sample size is small and follow-up is only one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Started

Mar 2023

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Caucasian premenopausal women between 18-39 years with the diagnosis of endometrioma, one or more, with a diameter of up to 7 cm by endovaginal ultrasound. Body mass index comprised between 17-30 Kg/m2.

Ages

18 to 39 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Caucasian premenopausal women between 18-39 years with the diagnosis of endometrioma, one or more, with a diameter of up to 7 cm by endovaginal ultrasound. Body mass index comprised between 17-30 Kg/m2 Exclusion Criteria: * Previous ovarian surgery; * Previous pathologies involving the ovary, including other ovarian tumors, polycystic ovaries, or pelvic inflammatory disease; * Previous diagnosis of cancer treated with chemotherapy or local radiotherapy; * Diseases affecting the endocrine system, diabetes, thyroid, hyperprolactinemia, or the immune system (lupus, Crohn,…); * Genesic wish; * Endometrioma \>7 cm; * Unhealthy habits, including smoking, alcohol consumption above social level, or illicit drugs; * Insufficient level of autonomy for unrestrictedly signing informed consent; * Current or previous use of hormonal contraceptives, Gonadotropin-Releasing Hormone (GnRH) analogues, any drug with a known effect on endometriosis, or any drug under investigation, for what a washing up period of 6 months will be required in all cases.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrioma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometriosis ovarian endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrioma

Contacts and locations

Locations

  • Hosp Clinico Universitario-INCLIVA

    Valencia, Valencia, 46010, Spain

  • University Hospital Poznan

    Poznan, Poznan, 60-355, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.